Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
30 participants
OBSERVATIONAL
2016-08-31
2019-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treponema Pallidum-specific Proteomic Changes in Patients With Incident Syphilis Infection
NCT02059525
Evaluation of the Performance of Chembio's DPP(R) Syphilis Screen & Confirm Rapid Test System
NCT01543295
Modernizing Perinatal Syphilis Testing
NCT06082453
Treponemal Shedding, Load, and Viability, in Women and Men-who-have-sex-with-women-only With Early Infectious Syphilis: Implications for Transmission
NCT07300254
Transcriptomic and Next Generation Sequencing Approaches to Infection With Treponema Pallidum
NCT03310424
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Serofast status
The syphilitic patients who remain in a serologically positive state after therapy
RPR Titer
RPR titer; TPPA/FTA-ABS; Next-Generation Sequencing
Untreated
untreated syphilis cases
RPR Titer
RPR titer; TPPA/FTA-ABS; Next-Generation Sequencing
Serological cure
In the early syphilis patients, at 6 months following treatment, a serological cure was defined as either a negative RPR or ≥2 dilution (4-fold) decrease in the RPR titer.
In the late syphilis patients, at 12 months following treatment, a serological cure was defined as either a negative RPR or ≥2 dilution (4-fold) decrease in the RPR titer.
RPR Titer
RPR titer; TPPA/FTA-ABS; Next-Generation Sequencing
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RPR Titer
RPR titer; TPPA/FTA-ABS; Next-Generation Sequencing
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Lyme disease
18 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Peking Union Medical College Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jun Li
Role: PRINCIPAL_INVESTIGATOR
Peking Union Medical College Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
PekingUMCH
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Jun Li
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
The reaseon of serofast
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.